A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
10.1038/35102591
Crossref journal-article
Springer Science and Business Media LLC
Nature (297)
Bibliography

Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., Kang, D. E., Marquez-Sterling, N., Golde, T. E., & Koo, E. H. (2001). A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature, 414(6860), 212–216.

Authors 14
  1. Sascha Weggen (first)
  2. Jason L. Eriksen (additional)
  3. Pritam Das (additional)
  4. Sarah A. Sagi (additional)
  5. Rong Wang (additional)
  6. Claus U. Pietrzik (additional)
  7. Kirk A. Findlay (additional)
  8. Tawnya E. Smith (additional)
  9. Michael P. Murphy (additional)
  10. Thomas Bulter (additional)
  11. David E. Kang (additional)
  12. Numa Marquez-Sterling (additional)
  13. Todd E. Golde (additional)
  14. Edward H. Koo (additional)
References 30 Referenced 1,102
  1. Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383–421 (2000). (10.1016/S0197-4580(00)00124-X) / Neurobiol. Aging by H Akiyama (2000)
  2. McGeer, P. L., Schulzer, M. & McGeer, E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425–432 (1996). (10.1212/WNL.47.2.425) / Neurology by PL McGeer (1996)
  3. Rogers, J. et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609–1611 (1993). (10.1212/WNL.43.8.1609) / Neurology by J Rogers (1993)
  4. Anthony, J. C. et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54, 2066–2071 (2000). (10.1212/WNL.54.11.2066) / Neurology by JC Anthony (2000)
  5. Stewart, W. F., Kawas, C., Corrada, M. & Metter, E. J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626–632 (1997). (10.1212/WNL.48.3.626) / Neurology by WF Stewart (1997)
  6. Smith, W. L., DeWitt, D. L. & Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145–182 (2000). (10.1146/annurev.biochem.69.1.145) / Annu. Rev. Biochem. by WL Smith (2000)
  7. Younkin, S. G. The role of Aβ42 in Alzheimer's disease. J. Physiol. Paris 92, 289–292 (1998). (10.1016/S0928-4257(98)80035-1) / J. Physiol. Paris by SG Younkin (1998)
  8. Murphy, M. P. et al. Presenilin 1 regulates pharmacologically distinct γ-secretase activities. Implications for the role of presenilin in γ-secretase cleavage. J. Biol. Chem. 275, 26277–26284 (2000). (10.1074/jbc.M002812200) / J. Biol. Chem. by MP Murphy (2000)
  9. McEvoy, G. K. AHFS Drug Information (American Society of Health-System Pharmacists, Bethesda, 1998). / AHFS Drug Information by GK McEvoy (1998)
  10. Janne, P. A. & Mayer, R. J. Chemoprevention of colorectal cancer. N. Engl. J. Med. 342, 1960–1968 (2000). (10.1056/NEJM200006293422606) / N. Engl. J. Med. by PA Janne (2000)
  11. Lim, G. P. et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709–5714 (2000). (10.1523/JNEUROSCI.20-15-05709.2000) / J. Neurosci. by GP Lim (2000)
  12. Piazza, G. A. et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57, 2452–2459 (1997). / Cancer Res. by GA Piazza (1997)
  13. Cryer, B. & Feldman, M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 104, 413–421 (1998). (10.1016/S0002-9343(98)00091-6) / Am. J. Med. by B Cryer (1998)
  14. Zhang, X., Morham, S. G., Langenbach, R. & Young, D. A. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190, 451–459 (1999). (10.1084/jem.190.4.451) / J. Exp. Med. by X Zhang (1999)
  15. Abdel-Halim, M. S., Sjoquist, B. & Anggard, E. Inhibition of prostaglandin synthesis in rat brain. Acta Pharmacol. Toxicol. 43, 266–272 (1978). (10.1111/j.1600-0773.1978.tb02264.x) / Acta Pharmacol. Toxicol. by MS Abdel-Halim (1978)
  16. Li, Y. M. et al. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689–694 (2000). (10.1038/35015085) / Nature by YM Li (2000)
  17. De Strooper, B. et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518–522 (1999). (10.1038/19083) / Nature by B De Strooper (1999)
  18. Hadland, B. K. et al. γ-secretase inhibitors repress thymocyte development. Proc. Natl Acad. Sci. USA 98, 7487–7491 (2001). (10.1073/pnas.131202798) / Proc. Natl Acad. Sci. USA by BK Hadland (2001)
  19. Yankner, B. A. et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245, 417–420 (1989). (10.1126/science.2474201) / Science by BA Yankner (1989)
  20. Oster-Granite, M. L., McPhie, D. L., Greenan, J. & Neve, R. L. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J. Neurosci. 16, 6732–6741 (1996). (10.1523/JNEUROSCI.16-21-06732.1996) / J. Neurosci. by ML Oster-Granite (1996)
  21. Perez, R. G. et al. Mutagenesis identifies new signals for β-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Aβ42. J. Biol. Chem. 274, 18851–18856 (1999). (10.1074/jbc.274.27.18851) / J. Biol. Chem. by RG Perez (1999)
  22. Kopan, R., Schroeter, E. H., Weintraub, H. & Nye, J. S. Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc. Natl Acad. Sci. USA 93, 1683–1688 (1996). (10.1073/pnas.93.4.1683) / Proc. Natl Acad. Sci. USA by R Kopan (1996)
  23. Wiltfang, J. et al. Improved electrophoretic separation and immunoblotting of β-amyloid (Aβ) peptides 1–40, 1–42, and 1–43. Electrophoresis 18, 527–532 (1997). (10.1002/elps.1150180332) / Electrophoresis by J Wiltfang (1997)
  24. Qiu, W. Q. et al. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J. Biol. Chem. 273, 32730–32738 (1998). (10.1074/jbc.273.49.32730) / J. Biol. Chem. by WQ Qiu (1998)
  25. Iwata, N. et al. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nature Med. 6, 143–150 (2000). (10.1038/72237) / Nature Med. by N Iwata (2000)
  26. Kang, D. E. et al. Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Invest. 106, 1159–1166 (2000). (10.1172/JCI11013) / J. Clin. Invest. by DE Kang (2000)
  27. McGeer, P. L. Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging 17, 1–11 (2000). (10.2165/00002512-200017010-00001) / Drugs Aging by PL McGeer (2000)
  28. Yuan, H. et al. Recombinant adenovirus is an appropriate vector for endocytotic protein trafficking studies in cultured neurons. J. Neurosci. Methods 88, 45–54 (1999). (10.1016/S0165-0270(99)00011-4) / J. Neurosci. Methods by H Yuan (1999)
  29. Wang, R., Sweeney, D., Gandy, S. E. & Sisodia, S. S. The profile of soluble amyloid β protein in cultured cell media. Detection and quantification of amyloid β protein and variants by immunoprecipitation-mass spectrometry. J. Biol. Chem. 271, 31894–31902 (1996). (10.1074/jbc.271.50.31894) / J. Biol. Chem. by R Wang (1996)
  30. Kawarabayashi, T. et al. Age-dependent changes in brain, CSF, and plasma amyloid (β) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372–381 (2001). (10.1523/JNEUROSCI.21-02-00372.2001) / J. Neurosci. by T Kawarabayashi (2001)
Dates
Type When
Created 23 years ago (July 26, 2002, 4:32 a.m.)
Deposited 2 years, 3 months ago (May 16, 2023, 10:14 p.m.)
Indexed 11 minutes ago (Aug. 24, 2025, 4:49 p.m.)
Issued 23 years, 9 months ago (Nov. 1, 2001)
Published 23 years, 9 months ago (Nov. 1, 2001)
Published Print 23 years, 9 months ago (Nov. 1, 2001)
Funders 0

None

@article{Weggen_2001, title={A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity}, volume={414}, ISSN={1476-4687}, url={http://dx.doi.org/10.1038/35102591}, DOI={10.1038/35102591}, number={6860}, journal={Nature}, publisher={Springer Science and Business Media LLC}, author={Weggen, Sascha and Eriksen, Jason L. and Das, Pritam and Sagi, Sarah A. and Wang, Rong and Pietrzik, Claus U. and Findlay, Kirk A. and Smith, Tawnya E. and Murphy, Michael P. and Bulter, Thomas and Kang, David E. and Marquez-Sterling, Numa and Golde, Todd E. and Koo, Edward H.}, year={2001}, month=nov, pages={212–216} }